Skip to main content
. 2021 Jul 24;13(15):3729. doi: 10.3390/cancers13153729

Figure 2.

Figure 2

hAFS and hMSC secretomes preserve mitochondrial transmembrane potential in mNVCM exposed to Dox. (A) Representative confocal images of live mNVCM in control condition (Ctrl), undergoing stimulation with either hAFS-CM (hAFS-CM) or hMSC-CM (hMSC-CM) for 3 h or exposed to 1 µM Dox for 16 h with or without (Dox) prior priming with hAFS-CM (hAFS-CM + Dox) or hMSC-CM (hMSC-CM + Dox) for 3 h. The cell mitochondrial network is represented in red by the MitoTracker signal, scale bar: 5 µm, (B) Mitochondrial transmembrane potential evaluated by MitoTracker fluorescence analysis and expressed by arbitrary units (A.U.) mNVCM treated as follows: control condition (n = 4, Ctrl: 351.85 ± 17.13); after exposure to 1 μM Dox for 16 h (n = 4, Dox: 167.52 ± 23.49); pretreated with hAFS-CM or hMSC-CM for 3 h before 1 μM Dox stimulation for 16 h (n = 4, hAFS-CM + Dox: 286.77 ± 12.94, and hMSC-CM + Dox: 254.57 ± 18.56, respectively), or only pretreated with hAFS-CM or hMSC-CM (n = 3, hAFS-CM: 421.63 ± 9.55 and hMSC-CM: 397.93 ± 9.57, respectively). Values are expressed as the mean ± SEM of the independent experiments. hAFS-CM vs. Ctrl and hMSC-CM vs. Ctrl: not significant; Ctrl vs. Dox; §§§§ p < 0.0001; hAFS-CM + Dox vs. Dox ** p = 0.0012; hMSC-CM +Dox vs. Dox * p = 0.0185.